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and moderate regurgitation in 1. Mean gradients were 6.1 ± 
5.0 mm Hg across the device. Postmortem examination con-
firmed adequate positioning of devices within the annulo-
plasty ring.  Conclusions: This custom-made transcatheter 
device allows for safe and reproducible off-pump transatrial 
mitral VIR implantations. Transatrial access is a promising 
route to facilitate VIR implantations. Our custom-made 
stent-valve may be suitable for VIR procedures. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Mitral valve repair is the preferred surgical therapy for 
mitral regurgitation. Annuloplasty rings are routinely 
used for restoring the mitral annular size and shape. The 
superiority of mitral valve repair over valve replacement 
has been shown  [1, 2] . However, the durability of mitral 
valve repair is not satisfactory, especially in patients 
with ischemic regurgitation. Some centers report that at 
6 months, up to 30% of patients suffer a recurrence of mi-
tral valve regurgitation following valve repair  [3–5] . Re-
operation after 10 years is necessary in 5–10% of these 
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 Abstract 
 Objectives: To validate a self-expanding transcatheter valve 
for off-pump transatrial mitral valve-in-ring (VIR) implanta-
tion via a left thoracotomy.  Methods: Mitral valve annulo-
plasty was performed via sternotomy during cardiopulmo-
nary bypass on 9 pigs. After successful weaning from extra-
corporal circulation, the custom-made, self-expanding 
transcatheter VIR device was deployed under fluoroscopic 
guidance within the annuloplasty ring via a left thoracoto-
my. Hemodynamic data before and after the implantation 
were recorded. Mitral annulus diameter and valve area were 
measured by echocardiography. Transvalvular and left-ven-
tricular outflow-tract pressure gradient were measured inva-
sively.  Results: Eight successful implantations were per-
formed. Implantation failed in 1 pig because of difficulty with 
technical delivery of the sheath. Mean transatrial procedure 
time was 12.6 ± 1.7 min. Hemodynamic status during 
transatrial implantation was stable, and differences were not 
statistically significant. Mean mitral annulus diameter and 
mean mitral orifice area were 2.32 ± 0.2 and 3.84 ± 0.55 cm 2 , 
respectively. Mild regurgitation was detected in 7 animals 
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patients  [2, 6] . Nevertheless, the high risk of repeat sur-
gery, especially in the case of elderly patients, must be 
considered.
 In the past decade, transcatheter valve replacement 
techniques have developed rapidly. Transfemoral and 
transapical transcatheter aortic valve implantation 
(TAVI) have shown very promising clinical results in se-
lected patient populations. Although transcatheter mi-
tral valve replacement has mostly remained at the stage 
of animal evaluation  [7, 8] , transcatheter mitral valve-in-
valve (VIV) or valve-in-ring (VIR) implantation has 
slowly entered clinical practice. The VIR technique turns 
out to be a potential therapeutic technique for high-risk 
patients with mitral repair failure. Nevertheless, only iso-
lated clinical cases and animal studies  [9–13] have been 
reported due to the challenge of matching the stent and 
the ring. Moreover, only balloon-expanding TAVI de-
vices like the Sapien or Melody valves  [9, 10, 12, 14] have 
been used.
 This study was designed to confirm the feasibility of 
transatrial transcatheter mitral VIR replacement via a left 
thoracotomy, without cardiopulmonary bypass (CPB) 
support and using a self-expanding dedicated nitinol de-
vice. We also wanted to evaluate its hemodynamic perfor-
mance in an acute porcine model.
 Materials and Methods 
 The Stent Valve 
 As described in our previous article  [8] , a 30-mm, self-expand-
ing nitinol stent frame was designed, using 2 self-expanding nitinol 
Z-stents covered by an ultrathin polytetrafluoroethylene mem-
brane. The stents were sutured together like 2 opposite crowns, 
creating a waist portion for the annular fixation. Next, a 30-mm-
diameter Dacron tube was attached at the center of the fixation 
system, accommodating an inhouse-built tricuspid-tissue valve 
made from commercially available bovine pericardium (BalMedic, 
Peking, P.R.C.;  fig. 1 a). All devices underwent thorough in vitro 
testing and were preserved in a glutaraldehyde solution prior to 
experimental in vivo use.
 The Delivery System  
 Device delivery was performed using a self-constructed deliv-
ery system made from a 30-cm-long Teflon sheath and a blunt-tip 
pusher by modification of an 18-french introducer sheath (B.
Braun Melsungen AG, Melsungen, Gemany). The distal end of the 
sheath was dilated to a 30-french inner-lumen diameter by inflat-
ing a 10-mm balloon (Boston Scientific Corp., Watertown, Mass., 
USA). According to the stent’s length, a 40-mm capsule was cre-
ated  [15] . The new valve device was then compressed with a com-
mercial crimper and loaded into the capsule. The valve deploy-
ment in the appropriate position was performed with a pusher into 
the sheath and without balloon catheters. The folded valve mea-
sured 10 mm in diameter and 40 mm in length ( fig. 1 b).
 Animal Preparation 
 The study was approved by the local Ethics Research Board. 
Animals received care in compliance with the ‘the Guide for the 
Care and Use of Laboratory Animals’ prepared by the Institute of 
Laboratory Animal Resources and published by the National In-
stitute of Health (NIH publication 85–23, revised 1985). 
 Nine porcine experiments (the mean body weight of the pigs 
was 61.1 ± 5.2 kg) were performed in this acute study. After under-
going general anesthesia with tracheal intubation and mechanical 
ventilation (ketamine 22 mg/kg and atropine 0.8 mg/kg intramus-
cularly, thiopental 15 mg/kg intravenously for induction and iso-
flurane 2.5% for maintenance anesthesia), the right carotid artery 
and internal jugular vein were exposed and catheters were intro-
duced to monitor the blood pressure and central venous pressure, 
and for blood sampling and infusion. The left carotid artery and 
the external jugular vein were prepared for cannulation for CPB. 
Arterial pressure, central venous pressure, oxygen saturation and 
electrocardiography were monitored continuously.
 Annuloplasty Ring Implantation 
 After standard sternotomy and heparinization (100 IU/kg), the 
native mitral annular diameter and area were measured by epicar-
dial echocardiography (Mindray, Shengzhen, China). CPB was es-
tablished with cannulation of the left carotid artery and external 
jugular vein. After aortic cross-clamping, antegrade cardioplegia 
 Fig. 1. Custom-made, self-expanding, double-crowned VIR device ( a ) and its delivery system ( b ).  c The 28-mm 
rigid annuloplasty ring was sewn to the mitral annulus under CPB (seen from the left side). 
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was administered and the heart was arrested. Following opening 
of the left atrium, a rigid and closed 28-mm mitral annuloplasty 
ring (Edwards Lifesciences, Irvine, Calif., USA) was sutured into 
the mitral annulus ( fig. 1 c). After confirming mitral valve compe-
tence with saline injection, the left atrial access was closed again 
and the aortic cross-clamp removed. Once successful weaned from 
CPB, a repeat epicardial echocardiography was performed. Inva-
sive transvalvular and left-ventricular outflow-tract (LVOT) pres-
sure gradient were taken as baseline values and the sternum was 
subsequently closed with a 0 # Maxon suture. 
 Transatrial Mitral Stent Valve Implantation 
 Via a fourth intercostal left-sided thoracotomy, a single purse-
string suture was placed at the left atrium. The annuloplasty ring 
was identified under fluoroscopy. In parallel, the self-expanding, 
valved device was prepared and loaded onto the delivery system. 
Through a 1-cm incision, the left atrium was entered with the cus-
tom-made delivery system. Under fluoroscopic guidance, the an-
nuloplasty ring was crossed and the device positioned in a 50/50 
fashion within the ring. Without rapid ventricular pacing, the ven-
tricular side of the stent was partially expanded by advancing the 
pusher. Next, the delivery system was gradually withdrawn until 
the anchoring portion of the stent was aligned with the ring. The 
delivery sheath was pulled continuously for atrial deployment of 
the device at the target ( fig. 2 a–f). Fluoroscopic guidance was used 
throughout the implantation.
 Device function and hemodynamic impact were assessed with 
epicardial echocardiography and angiography at baseline and 30 
min after implantation. The transprosthetic and trans-LVOT pres-
sure gradient were measured invasively. Continuous hemodynam-
ic measurements were taken for another hour and the animals 
were then electively sacrificed for postmortem examination and 
inspection of the device.
 Statistical Analysis 
 Data were analyzed with SPSS v19 software for Windows. Vari-
ables are reported as mean ± standard deviation (SD), and Stu-
dent’s t test was used for comparison.
 Results 
 All animals underwent successful surgical placement 
of an annuloplasty ring. The mean cardiac arrest time and 
CPB time were 49.3 ± 11.7 and 74.1 ± 14.7 min, respec-
tively. In 8 animals, successful transatrial mitral VIR im-
plantation was performed. In 1 animal, positioning the 
device failed because the delivery sheath was withdrawn 
too fast which caused the device to migrate into the left 
ventricle. The mean procedure time defined from placing 
the purse-string to tightening the purse-string tightening 
was 12.6 ± 1.7 min. Mean flow time was 6.3 + 3.2 min. 
Hemodynamic data before and after transatrial valve de-
ployment appear in  table 1 .
 The mean diameter of the native mitral annulus was 
2.58 ± 0.22 cm, and the mean mitral valve area was 4.58 ± 
0.29 cm 2 on echocardiography evaluation. Comparatively, 
the mean diameter and mean functional area of the self-
expanding device after implantation were 2.32 ± 0.2 and 
3.84 ± 0.55 cm 2 , respectively. No statistical difference ex-
isted in mitral diameter before and after implantation. 
However, the functional area before and after the proce-
dure were significantly different (i.e. p = 0.012 and p < 0.05). 
Of the 8 successful implants, all valve leaflets had normal 
mobility and function ( fig. 3 a, b). Trace or mild central re-
gurgitation was detected in 7 valves; in 1, a moderate central 
regurgitation was shown due to interaction with the Da-
cron device cover. No paravalvular leak between the stent 
frame and the annuloplasty ring was observed ( table 1 ).
a b
c d
e f
 Fig. 2.  a The mitral annuloplasty ring is radiopaque.  b The self-
expanding device is delivered across the ring via release of the ven-
tricular side first, by advancing the delivery pusher ( c ).  d ,  e Under 
gentle pull-back, the delivery sheath is pulled to continuously de-
ploy the atrial side.  f Precise device implantation is achieved at 
target position within the ring. 
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 Mean pressure gradient across the self-expanding de-
vice was 6.1 ± 5.0 mm Hg. The corresponding gradients 
across the LVOT were 4.8 ± 3.0 mm Hg ( table 1 ).
 Postmortem examinations confirmed the precise de-
vice positioning within the annuloplasty rings in 8 ani-
mals with no signs of LVOT obstruction ( fig. 4 a, b).
 Discussion 
 Transcatheter replacement of the native mitral valve 
has been reported previously  [16] . However, due to the 
complex anatomic structure of the mitral valve apparatus 
and the absence of a reliable ‘landing zone’  [10] , most re-
sults are from animal experiments only  [7] . VIV and VIR 
implantation techniques into the mitral position haven 
been clinically introduced more successfully. Avoiding 
reoperation and standardizing the ‘landing zone’ of 
 previously placed bioprosthesis or annuloplasty rings 
support the drive for dedicated VIV and VIR device de-
velopment. The in situ bioprosthesis as well as the mitral 
annuloplasty ring provide distinctive fluoroscopic land-
marks  [17] . The congruence between valve and prosthe-
sis/annulus is a key factor for avoiding paravalvular 
 regurgitation  [18] . In contrast to the straightforward VIV 
implantations into a circular mitral valve bioprosthesis 
 Table 1.  Procedural data and hemodynamic and implanted stent valve function
No. Weight,
kg
HRa, bpm BPa, mm Hg CVPa,
mm Hg
Valve diametera, 
cm
Valve area, 
 cm2
Arrest
time,
min
CPB
time,
min
Transapical
time,
min
Across
valve,
mm Hg
Across
LVOT,
mm Hg
pre post pre post pre post native stent nativ e stent
1 60 106 135 100/77 91/50 10 8 2.52 2.50 4.70 4.10 35 50 10 7 3
2 63 114 90 83/47 88/55 8 7 2.43 2.40 4.63 4.02 50 65 12 3 7
3 54 104 97 83/54 87/72 7 8 2.60 2.10 4.21 3.81 35 65 15 4 2
4 70 101 113 86/50 83/43 9 6 2.58 2.16 4.20 3.62 60 90 13 4 1
5 67 92 n.a. 115/63 n.a. 12 n.a. 2.61 n.a. 6.01 n.a. 43 63 15 n.a. n.a.
6 57 100 96 111/77 103/68 11 7 3.10 2.00 4.85 2.59 65 90 12 18 6
7 61 114 103 93/66 94/37 7 6 2.45 2.50 4.91 4.24 60 85 13 3 4
8 56 86 97 90/56 95/52 8 7 2.50 2.40 4.37 4.11 39 70 11 5 5
9 62 90 100 103/62 98/56 7 9 2.47 2.52 4.80 4.21 57 89 12 5 10
Mean 61.1 101.9 103.9 93.6/61.1 92.4/54.1 8.4 7.3 2.58 2.32 4.58 3.84 49.3 74.1 12.6 6.1 4.8
SD 5.2 10.1 14.2 10.2/11.5 6.5/11.7 1.5 1.0 0.22 0.21 0.29 0.55 11.7 14.7 1.7 5.0 2.9
 Across LVOT = Gradient across LVOT; Across valve = gradient across valve; BP = blood pressure; CVP = central venous pressure; HR = heart rate; n.a.  = 
not available (due to failed implantation); post = after VIR placement; pre = before VIR placement; SD = standard deviation.
a Differences between hemodynamics before and after the VIR implantation were not statistically significant.
a b
 Fig. 3. Epicardial echocardiography revealed excellent device function with complete leaflet opening ( a ) and 
 closing ( b ).  
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 [19–21] , the ‘D’ shaped mitral valve annuloplasty ring 
presents an important challenge for TAVI devices. Malap-
position and noncircularity might lead to leaflet malco-
aptation, resulting in regurgitation and early degenera-
tion of the device. The overall experience of VIR is  mostly 
limited to isolated clinical case reports, small series and 
animal studies  [10, 14, 22–24] . Descoutures et al.  [10] re-
ported preliminary multicenter results of 17 cases, and 
that VIR may provide short-term clinical and hemody-
namic improvement.
 There are 3 accesses that are favorable for transcath-
eter VIR implantation, i.e. transapical, transseptal and 
transatrial. The transapical access has become a routine 
approach due to its safety, reproducibility and low com-
plication rate. Allowance for the implantation of large-
size devices and a short access to both the mitral and the 
aortic valve are further advantages  [17] . However, it does 
have some shortcomings. On the one hand, the mitral 
valve apparatus interferes with the delivery system while 
crossing the mitral valve  [7] and on the other, a surgical 
cutdown and manipulation of the left ventricular apex 
are necessary. The transseptal approach is a frequently 
used percutaneous technique  [25] . However, with this 
access, there is a clear need for advanced interventional 
skills and associated learning  [10] . Despite being an an-
tegrade access to the mitral valve, due to the long wires 
and catheters, device positioning and delivery is less pre-
cise  [11] . The other antegrade approach is the transatrial 
access that offers distinct advantages for mitral implants, 
namely (1) the ease of antegrade valve crossing, (2) atrial 
access with eased bleeding control, (3) a more linear and 
coaxial angle to the mitral valve  [24] and (4) a short 
working distance with easier stabilization for device de-
ployment  [10] . Our study confirms the eased mitral valve 
crossing using the transatrial rather than the transapical 
access  [13] .
 In this study, we successfully performed transatrial mi-
tral VIR implantations using a custom-made, dedicated 
VIR device. In 8 of the 9 porcine experiments, stable he-
modynamics were achieved throughout the procedure. 
This finding validates the feasibility of off-pump transatri-
al mitral VIR implantations via a left thoracotomy with 
the use of our self-expanding device.
 However, we did detect a moderate central regurgita-
tion in 1 case. Postmortem examination found that the 
soft Dacron tube was partially deformed and the resulting 
interaction with the device leaflet led to malcoaptation of 
the cusps and subsequent regurgitation. In addition, de-
vice itinerations are necessary to improve the ring device 
interaction.
 In our study, the transvalvular gradient pressures 
were suboptimal because of the amount of material with-
in the stent. As described above, a Dacron tube for ac-
commodating a valve was an extra component in our 
stent. Moreover, this tube was soft and might have be-
come partly deformed while the blood flowed through it. 
All of these factors resulted in higher transvalvular gradi-
ent pressures. The next generation of our stent will be 
designed with a rigid tube, which will replace the soft 
tube to support the valve, avoiding an excess of extra 
components in the direction of the blood flow. The di-
ameter of our stent valve remained constant. We could 
not choose the proper stent valve according to annulus 
diameter. We have taken this into consideration. The 
next generation of stent valve will be designed on the ba-
sis of a different annulus diameter, thus providing a bet-
 Fig. 4. Postmortem examination revealed accurate delivery without LVOT obstruction.  a Left atrial side.  b Left 
ventricular side. 
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ter foundation of its usefulness in human experiments in 
future.
 So far, the balloon-expandable transcatheter heart 
valve is the only available valve used in reports on mitral 
VIV or VIR procedures  [10] . There are several disadvan-
tages to be mentioned when comparing balloon-expand-
able to self-expanding devices: (1) the need for rapid ven-
tricular pacing, (2) malpostioning, i.e. either too atrial or 
too ventricular  [10, 25] and (3) the effective valve orifice 
after implantation is much lower than the area of native 
mitral valve  [10, 25] . Based on our previous  [13] and cur-
rent studies, we can say that the self-expanding, double-
crown device achieves a self-centering and self-aligning 
anchoring into the annuloplasty ring. Due to the supra-
annular implantation, our device resulted in a larger ef-
fective orifice after implantation. The functional area af-
ter the implantation was 3.84 ± 0.55 cm 2 , approximating 
the native valve area of 4.58 ± 0.29 cm 2 . These results 
were also in line with our previously published results 
 [13] .
 There are many reasons for the recurrence of mitral 
valve regurgitation following valve repair. Our custom-
made stent valve expands completely to get an ideal ef-
fectiveness for patients with a flexible valve, whose recur-
rence of mitral valve regurgitation may be caused by frac-
ture of the manual chordae tendineae or ischemia. 
However, for the recurrence of mitral valve regurgitation 
caused by rheumatic heart disease or degeneration of the 
valve, the presence of calcific or rigid valve not only prob-
ably leads to our custom-made stent valve expanding un-
completely, deforming or displacement, but also affects 
the delivery of the stent. Balloon dilatation should be ap-
plied several times before mitral VIR implantations to get 
a large effective orifice area.
 It is evident that there are differences between a dys-
functional and a normal mitral valve; we have taken this 
into account for our next experiment. A model of a dys-
functional mitral valve will be made to test our self-ex-
panding VIR device for its accommodation in treatment 
for the recurrence of mitral valve regurgitation following 
valve repair.
 In conclusion, this study demonstrated the feasibility 
of transatrial mitral VIR implantation via a left thoracot-
omy, without extracorporeal circulation and using a ded-
icated, double-crowned, self-expanding VIR device. The 
larger effective orifice area and the suprannular fixations 
are major advantages over the currently used balloon-ex-
pandable device.
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